Rubenfire M - Search Results

1

Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.

Rubenfire M, McLaughlin VV, Allen RP, Elliott G, Park MH, Wade M, Schilz R. Rubenfire M, et al. Chest. 2007 Sep;132(3):757-63. doi: 10.1378/chest.06-2118. Epub 2007 Mar 30. Chest. 2007. PMID: 17400684 Clinical Trial.

2

How to manage primary pulmonary hypertension. Giving hope to patients with a life-threatening illness.

Ricciardi MJ, Rubenfire M. Ricciardi MJ, et al. Among authors: rubenfire m. Postgrad Med. 1999 Mar;105(3):45-8, 51-6. doi: 10.3810/pgm.1999.03.596. Postgrad Med. 1999. PMID: 10086033 Review.

3

Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing.

Ricciardi MJ, Bossone E, Bach DS, Armstrong WF, Rubenfire M. Ricciardi MJ, et al. Among authors: rubenfire m. Chest. 1999 Nov;116(5):1218-23. doi: 10.1378/chest.116.5.1218. Chest. 1999. PMID: 10559078 Clinical Trial.

4

Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension.

Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Paciocco G, et al. Among authors: rubenfire m. Eur Respir J. 2001 Apr;17(4):647-52. doi: 10.1183/09031936.01.17406470. Eur Respir J. 2001. PMID: 11401059 Free article.

5

Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.

Hoeper MM, Galié N, Murali S, Olschewski H, Rubenfire M, Robbins IM, Farber HW, McLaughlin V, Shapiro S, Pepke-Zaba J, Winkler J, Ewert R, Opitz C, Westerkamp V, Vachiéry JL, Torbicki A, Behr J, Barst RJ. Hoeper MM, et al. Among authors: rubenfire m. Am J Respir Crit Care Med. 2002 Feb 1;165(3):341-4. doi: 10.1164/ajrccm.165.3.200109-0130c. Am J Respir Crit Care Med. 2002. PMID: 11818318

6

The prognostic role of the ECG in primary pulmonary hypertension.

Bossone E, Paciocco G, Iarussi D, Agretto A, Iacono A, Gillespie BW, Rubenfire M. Bossone E, et al. Among authors: rubenfire m. Chest. 2002 Feb;121(2):513-8. doi: 10.1378/chest.121.2.513. Chest. 2002. PMID: 11834666

7

The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect.

Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM, Shapiro S, Tapson VF, Zwicke D, DeMarco T, Schilz R, Rubenfire M, Barst RJ. Frost AE, et al. Among authors: rubenfire m. Vascul Pharmacol. 2005 Jun;43(1):36-9. doi: 10.1016/j.vph.2005.03.003. Vascul Pharmacol. 2005. PMID: 15890561 Clinical Trial.

8

Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need.

Rubenfire M, Lippo G, Bodini BD, Blasi F, Allegra L, Bossone E. Rubenfire M, et al. Chest. 2009 Aug;136(2):597-603. doi: 10.1378/chest.08-1260. Chest. 2009. PMID: 19666759 Review.

9

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. McLaughlin VV, et al. Among authors: rubenfire m. J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027. J Am Coll Cardiol. 2010. PMID: 20430262 Free article. Clinical Trial.

10

Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension?

Cornwell WK, McLaughlin VV, Krishnan SM, Rubenfire M. Cornwell WK, et al. Among authors: rubenfire m. Chest. 2011 Sep;140(3):697-705. doi: 10.1378/chest.10-3019. Epub 2011 May 26. Chest. 2011. PMID: 21622545

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

246 results

Search Page